Clinical Trial Update: Phase II Trial of EOquin in High-risk Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase II trial results for EOquin in high-risk superficial bladder cancer have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• EOquin

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Neoplasms | Phase 2 | Status: COMPLETED